Influence of tumor peroxisome proliferator-activated receptor γ and δ expression on postoperative mortality of patients undergoing colorectal cancer surgery

Journal of Investigative Surgery

Volumn 22, Issue 2, 2009, Pages 105-111

  Ishizuka, Mitsuru ^a   Sawada, Tokihiko ^a   Okada, Toshie ^a   Nagata, Hitoshi ^a   Takagi, Kazutoshi ^a   Horie, Toru ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Postoperative mortality; PPAR ; PPAR ; PPAR staging; Predictor

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; KAPLAN MEIER METHOD; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SURGICAL MORTALITY; COLORECTAL TUMOR; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PPAR DELTA; PPAR GAMMA; RETROSPECTIVE STUDIES;

EID: 66149093066     PISSN: 08941939     EISSN: 15210553     Source Type: Journal    
DOI: 10.1080/08941930802713084     Document Type: Article

References (25)

1. Ajiki W, Tsukuma H, Oshima A, et al.. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol. 2004;34:352-356.
2. Chao A, Thun MJ, Connell CJ, et al.. Meat consumption and risk of colorectal cancer. JAMA. 2005;293:172-182.
3. Kuriki K, Hirose K, Matsuo K, et al.. Meat, milk, saturated fatty acids, the Pro12Ala and C161T polymorphisms of the PPARgamma gene and colorectal cancer risk in Japanese. Cancer Sci. 2006;97:1226-1235.
4. Meyerhardt JA, Niedzwiecki D, Hollis D, et al.. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA. 2007;298:754-764.
5. KoefflerHP. Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res. 2003;9:1-9.
6. Issemann I, Prince RA, Tugwood JD, et al.. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol. 1993;11:37-47.
7. Lefebvre M, Paulweber B, Fajas L, et al.. Peroxisome proliferatoractivated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol. 1999;162:331-340.
8. Gupta RA, Dubois RN. Controversy: PPARgamma as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2002;283:266-269.
9. Osawa E, Nakajima A, Wada K, et al.. Peroxisome proliferatoractivated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology. 2003;124:361-367.
10. Rumi MA, Ishihara S, Kazumori H, et al.. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents. 2004;4:465-477.
11. Cesario RM, Stone J, Yen WC, et al.. Differentiation and growth inhibition mediated via the RXR: PPARgamma heterodimer in colon cancer. Cancer Lett. 2006;240:225-233.
12. Kitamura S, Miyazaki Y, Shinomura Y, et al.. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 1999;90:75-80.
13. Lu J, Imamura K, Nomura S, et al.. Chemopreventive effect of peroxisome proliferator-activated receptor gamma on gastric carcinogenesis in mice. Cancer Res. 2005;65:4769-4774.
14. Harman FS, Nicol CJ, Marin HE, et al.. Peroxisome proliferatoractivated receptor-delta attenuates colon carcinogenesis. Nat Med. 2004;10:481-483.
15. Takayama O, Yamamoto H, Damdinsuren B, et al.. Expression of PPARdelta in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br J Cancer 2006;95:889-895.
16. Linsalata M, Giannini R, Notarnicola M, et al.. Peroxisome proliferator-activated receptor gamma and spermidine/ spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer 2006;6:191.
17. Theocharis S, Giaginis C, Parasi A, et al.. Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlationwith histopathological parameters, cell cycle-related molecules, and patients' survival. Dig Dis Sci. 2007;52:2305-2311.
18. Yang L, Zhou ZG, Luo HZ, et al.. Quantitative analysis of PPARdelta mRNA by real-time RT-PCR in 86 rectal cancer tissues. Eur J Surg Oncol. 2006;32:181-185.
19. Sarraf P, Mueller E, SmithWM,et al.. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell. 1999;3;799-804.
20. Marin HE, Peraza MA, Billin AN, et al.. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 2006;66:4394-4401.
21. Gupta RA, Tan J, Krause WF, et al.. Prostacyclin-mediated activation of PPAR delta in colorectal cancer. Proc Natl Acad Sci USA. 2000;97:13275-13280.
22. He TC, Chan TA, Vogelstein B, et al.. PPAR delta is an APCregulated target of nonsteroidal anti-inflammatory drugs. Cell. 1999;99:335-345.
23. Park BH, Vogelstein B, Kinzler KW, et al.. Genetic disruption of PPAR delta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA. 2001;98:2598-2603.
24. Yang L, Zhou ZG, Zhang XL, et al.. RNA interference against peroxisome proliferator-activated receptor delta gene promotes proliferation of human colorectal cancer cells. Dis Colon Rectum. 2008;51:318-326.
25. Xu F, Wang F, Di M, et al.. Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma. Clin Cancer Res. 2007;13:5082-5088.